Filing Flows › ADC Therapeutics SA (ADCT) › Stock forecast & fair value
ADC Therapeutics SA (ADCT) stock forecast and price target
ADC Therapeutics SA (ADCT) trades at $1.58. 3 analysts' median price target is $3.00 (+90%), from $2.00 to $5.00.
ADC Therapeutics SA's latest quarter
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ADCT stock?
The median of 3 analysts' 12-month targets is $3.00, +90% from $1.58; the range is $2.00 to $5.00. The average rating is none.
Does ADC Therapeutics SA usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is ADCT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.